☰

Samuel K. Kulp, D.V.M., Ph.D. - Publications

Affiliations: 
2001 Veterinary Biosciences Ohio State University, Columbus, Columbus, OH 
 2002-2017 Medicinal Chemistry Ohio State University, Columbus, Columbus, OH 
 2018- Pharmaceutics and Pharmaceutical Chemistry Ohio State University, Columbus, Columbus, OH 
Tree Info Similar researchers PubMed Report error

110 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Liva SG, Tseng YC, Dauki AM, Sovic MG, Vu T, Henderson SE, Kuo YC, Benedict JA, Zhang X, Remaily BC, Kulp SK, Campbell M, Bekaii-Saab T, Phelps MA, Chen CS, et al. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor. Embo Molecular Medicine. e9910. PMID 31930715 DOI: 10.15252/Emmm.201809910  0.344
2020 Lu C, Yang D, Klement JD, Oh K, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce C, Xie Z, Kulp S, Coss C, Phelps MA, Albers T, et al. Abstract A32: The SUV39H1-H3K9me3 pathway represses cytotoxic T lymphocyte effector expression to confer colon carcinoma immune escape Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-A32  0.354
2019 Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS. Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor. Molecular Cancer Therapeutics. 18: 869. PMID 30936413 DOI: 10.1158/1535-7163.Mct-19-0151  0.461
2019 Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff M, Oberlies NH, Pearce C, Xie Z, Kulp SK, Coss CC, Phelps MA, Albers T, et al. SUV39H1 represses the expression of cytotoxic T-lymphocyte effector genes to promote colon tumor immune evasion. Cancer Immunology Research. PMID 30610059 DOI: 10.1158/2326-6066.Cir-18-0126  0.345
2017 Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. Bmc Cancer. 17: 67. PMID 28109246 DOI: 10.1186/S12885-017-3046-6  0.38
2017 Wu H, Yang M, Chu P, Kulp SK, Chen C. Abstract 1360: Novel function of p21-activated kinase 3 (PAK3) in regulating Akt phosphorylation and pancreatic cancer stem cell phenotypes Cancer Research. 77: 1360-1360. DOI: 10.1158/1538-7445.Am2017-1360  0.439
2016 Chu PC, Kulp SK, Bekaii-Saab T, Chen CS. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. Small Gtpases. 1-5. PMID 27936345 DOI: 10.1080/21541248.2016.1251383  0.419
2016 Henderson SE, Ding LY, Mo X, Bekaii-Saab T, Kulp SK, Chen CS, Huang PH. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia (New York, N.Y.). 18: 765-774. PMID 27889645 DOI: 10.1016/J.Neo.2016.10.003  0.369
2016 Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen CS, Kulp SK. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie. PMID 27555377 DOI: 10.1016/J.Etp.2016.08.001  0.435
2016 Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW, Tseng YC, Yang MC, Salunke SB, Sullivan NJ, Chen WC, Zhang J, Teng CM, Fu WM, Sun D, Wicha MS, et al. Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. Carcinogenesis. PMID 26905583 DOI: 10.1093/Carcin/Bgw020  0.332
2015 Chao MW, Chu PC, Chuang HC, Shen FH, Chou CC, Hsu EC, Himmel LE, Huang HL, Tu HJ, Kulp SK, Teng CM, Chen CS. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability. Oncotarget. PMID 26625202 DOI: 10.18632/Oncotarget.6427  0.471
2015 Chu PC, Yang MC, Kulp SK, Salunke SB, Himmel LE, Fang CS, Jadhav AM, Shan YS, Lee CT, Lai MD, Shirley LA, Bekaii-Saab T, Chen CS. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. Oncogene. PMID 26616862 DOI: 10.1038/Onc.2015.458  0.428
2015 Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. Journal of the National Cancer Institute. 107. PMID 26464423 DOI: 10.1093/Jnci/Djv274  0.374
2015 Dokla EM, Fang CS, Lai PT, Kulp SK, Serya RA, Ismail NS, Abouzid KA, Chen CS. Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators. Chemmedchem. PMID 26350292 DOI: 10.1002/Cmdc.201500371  0.385
2015 Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ, Sun D, Wicha MS, Shapiro CL, Chen CS. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae. Neoplasia (New York, N.Y.). 17: 497-508. PMID 26152358 DOI: 10.1016/J.Neo.2015.06.001  0.415
2015 Chou CC, Chuang HC, Salunke SB, Kulp SK, Chen CS. A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells. Oncotarget. 6: 8271-85. PMID 25821081 DOI: 10.18632/Oncotarget.3186  0.375
2015 Yan R, Chuang HC, Kapuriya N, Chou CC, Lai PT, Chang HW, Yang CN, Kulp SK, Chen CS. Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors. Journal of Medicinal Chemistry. 58: 2290-8. PMID 25689347 DOI: 10.1021/Jm501751B  0.379
2015 Berman-Booty LD, Thomas-Ahner JM, Bolon B, Oglesbee MJ, Clinton SK, Kulp SK, Chen CS, La Perle KM. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicologic Pathology. 43: 186-97. PMID 24742627 DOI: 10.1177/0192623314531351  0.351
2015 Wu C, Lin P, Chu P, Chuang H, Kulp S, Bekaii-Saab T, Chen C. Abstract 5424: Therapeutic targeting of KRAS mutation-driven tumor progression in colorectal cancer Cancer Research. 75: 5424-5424. DOI: 10.1158/1538-7445.Am2015-5424  0.382
2014 Lo JH, Kulp SK, Chen CS, Chiu HC. Sensitization of intracellular Salmonella enterica serovar Typhimurium to aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent. Antimicrobial Agents and Chemotherapy. 58: 7375-82. PMID 25267669 DOI: 10.1128/Aac.03778-14  0.316
2014 Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CS. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Research. 74: 4783-95. PMID 24994714 DOI: 10.1158/0008-5472.Can-14-0135  0.47
2014 Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis. 35: 2203-13. PMID 24879635 DOI: 10.1093/Carcin/Bgu124  0.405
2014 Chou CC, Salunke SB, Kulp SK, Chen CS. Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents. Journal of Cellular Biochemistry. 115: 611-24. PMID 24166934 DOI: 10.1002/Jcb.24704  0.319
2014 Tseng Y, Kulp S, Lai I, He W, Bundschuh R, Frankhouser D, Yan P, Guttridge D, Marcucci G, Chen C, Bekaii-Saab T. Abstract 5540: Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia Cancer Research. 74: 5540-5540. DOI: 10.1158/1538-7445.Am2014-5540  0.389
2014 Chu P, Yang M, Kulp SK, Chen C. Abstract 4455: Targeting a novel kras-integrin-linked kinase regulatory circuitry in pancreatic cancer Cancer Research. 74: 4455-4455. DOI: 10.1158/1538-7445.Am2014-4455  0.453
2013 Chu PC, Kulp SK, Chen CS. Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent. Carcinogenesis. 34: 2694-705. PMID 23864387 DOI: 10.1093/Carcin/Bgt251  0.333
2013 Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu PC, Kulp SK, Byrd JC, Chen CS. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines. Plos One. 8: e67149. PMID 23840605 DOI: 10.1371/Journal.Pone.0067149  0.426
2013 Yang YL, Huang PH, Chiu HC, Kulp SK, Chen CS, Kuo CJ, Chen HD, Chen CS. Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism. Biochemical and Biophysical Research Communications. 435: 107-12. PMID 23624506 DOI: 10.1016/J.Bbrc.2013.04.049  0.432
2013 Huang PH, Chuang HC, Chou CC, Wang H, Lee SL, Yang HC, Chiu HC, Kapuriya N, Wang D, Kulp SK, Chen CS. Vitamin E facilitates the inactivation of the kinase Akt by the phosphatase PHLPP1. Science Signaling. 6: ra19. PMID 23512990 DOI: 10.1126/Scisignal.2003816  0.317
2013 Shidaifat F, Kulp SK, Lin YC. Zeranol induces deleterious effects on the testes and the prostate gland of mature rats. Endocrine Research. 38: 232-41. PMID 23496416 DOI: 10.3109/07435800.2013.774410  0.57
2013 Berman-Booty LD, Chu PC, Thomas-Ahner JM, Bolon B, Wang D, Yang T, Clinton SK, Kulp SK, Chen CS. Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent. Cancer Prevention Research (Philadelphia, Pa.). 6: 232-41. PMID 23275006 DOI: 10.1158/1940-6207.Capr-12-0057  0.452
2013 Chou C, Lee S, Kulp SK, Chen C. Abstract 3958: T315, a novel integrin-linked kinase inhibitor, suppresses hypoxia-induced epithelial-to-mesenchymal transition in prostate cancer. Cancer Research. 73: 3958-3958. DOI: 10.1158/1538-7445.Am2013-3958  0.489
2012 Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA. Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. Bmc Veterinary Research. 8: 244. PMID 23244668 DOI: 10.1186/1746-6148-8-244  0.419
2012 Chu PC, Chuang HC, Kulp SK, Chen CS. The mRNA-stabilizing factor HuR protein is targeted by β-TrCP protein for degradation in response to glycolysis inhibition. The Journal of Biological Chemistry. 287: 43639-50. PMID 23115237 DOI: 10.1074/Jbc.M112.393678  0.305
2012 Wei S, Chu PC, Chuang HC, Hung WC, Kulp SK, Chen CS. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. Plos One. 7: e47298. PMID 23071779 DOI: 10.1371/Journal.Pone.0047298  0.419
2012 Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Research and Treatment. 134: 649-59. PMID 22678161 DOI: 10.1007/S10549-012-2106-5  0.454
2012 Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle KM, Chen CS, Chang LS, Welling DB. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122: 174-89. PMID 22109824 DOI: 10.1002/Lary.22392  0.382
2012 Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, Kulp SK. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicologic Pathology. 40: 5-17. PMID 22021166 DOI: 10.1177/0192623311425062  0.313
2011 Bhinder AS, Varma V, Abbaoui B, Thomas-Ahner JM, Kulp SK, Chen C, Clinton SK, Mortazavi A. Antitumor effects of AR-42, a novel histone deacetylase inhibitor, in embryonal carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 232. PMID 27968650 DOI: 10.1200/Jco.2011.29.7_Suppl.232  0.4
2011 McCleese JK, Bear MD, Kulp SK, Mazcko C, Khanna C, London CA. Met interacts with EGFR and Ron in canine osteosarcoma. Veterinary and Comparative Oncology. 11: 124-39. PMID 22235915 DOI: 10.1111/J.1476-5829.2011.00309.X  0.38
2011 Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, Shapiro CL, Chen CS. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. The Journal of Biological Chemistry. 286: 39247-58. PMID 21917926 DOI: 10.1074/Jbc.M111.264598  0.432
2011 Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS. Identification and characterization of a novel integrin-linked kinase inhibitor. Journal of Medicinal Chemistry. 54: 6364-74. PMID 21823616 DOI: 10.1021/Jm2007744  0.473
2011 Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13: 983-99. PMID 21778190 DOI: 10.1093/Neuonc/Nor072  0.445
2011 Li H, Piao L, Xu P, Ye W, Zhong S, Lin SH, Kulp SK, Mao Y, Cho Y, Lee LJ, Lee RJ, Lin YC. Liposomes containing (-)-gossypol-enriched cottonseed oil suppress Bcl-2 and Bcl-xL expression in breast cancer cells. Pharmaceutical Research. 28: 3256-64. PMID 21710341 DOI: 10.1007/S11095-011-0498-2  0.644
2011 Bai LY, Ma Y, Kulp SK, Wang SH, Chiu CF, Frissora F, Mani R, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy N. OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway. British Journal of Haematology. 153: 623-33. PMID 21470196 DOI: 10.1111/J.1365-2141.2010.08443.X  0.366
2011 Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen CS. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 53: 1943-58. PMID 21391227 DOI: 10.1002/Hep.24293  0.336
2011 Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, Kulp SK, Teng CM, Wang Q, Chen CS. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. The Journal of Biological Chemistry. 286: 9968-76. PMID 21282102 DOI: 10.1074/Jbc.M110.203240  0.408
2011 Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells. Hepatology (Baltimore, Md.). 53: 148-59. PMID 21254166 DOI: 10.1002/Hep.23964  0.333
2011 Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK, Teng CM, Byrd JC, Chen CS. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Molecular Pharmacology. 79: 197-206. PMID 20959362 DOI: 10.1124/Mol.110.067702  0.332
2011 Chuang H, Kapuriya N, Wang D, Kulp SK, Shapiro CL, Chen C. Abstract 3505: Energy restriction-mimetic agents (ERMAs) decrease BRCA1 expression levels in triple-negative breast cancer cells: A rationale for combining ERMAs with poly(ADP ribose) polymerase Cancer Research. 71: 3505-3505. DOI: 10.1158/1538-7445.Am2011-3505  0.497
2011 Mishra A, Sams GH, Johns J, Curphey DP, Sullivan LA, Falkenberg LG, Gibson H, Liu S, Jaroncyk L, Carson W, Kulp SK, Chen C, Wong HK, Perle KL, Porcu P, et al. Abstract 2858: A novel mouse model for cutaneous T-cell lymphoma reveals a role for IL-15 and activity of a new oral HDAC inhibitor Cancer Research. 71: 2858-2858. DOI: 10.1158/1538-7445.Am2011-2858  0.307
2011 Lee S, Hsu E, Chuang H, Kulp S, Chen C. Abstract 1360: Design, synthesis, and target validation of T315, a putative ILK inhibitor Cancer Research. 71: 1360-1360. DOI: 10.1158/1538-7445.Am2011-1360  0.406
2010 McMahon MB, Bear MD, Kulp SK, Pennell ML, London CA. Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. American Journal of Veterinary Research. 71: 799-808. PMID 20594083 DOI: 10.2460/Ajvr.71.7.799  0.339
2010 Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. Plos One. 5: e10941. PMID 20532179 DOI: 10.1371/Journal.Pone.0010941  0.362
2010 Weng JR, Omar HA, Kulp SK, Chen CS. Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. Mini Reviews in Medicinal Chemistry. 10: 398-404. PMID 20370707 DOI: 10.2174/138955710791330945  0.38
2010 Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood. 115: 4217-25. PMID 20233974 DOI: 10.1182/Blood-2009-07-231985  0.456
2010 Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li PK, Li C, Fuchs J, Lin J. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Research. 70: 2445-54. PMID 20215512 DOI: 10.1158/0008-5472.Can-09-2468  0.485
2010 Guh JH, Chang WL, Yang J, Lee SL, Wei S, Wang D, Kulp SK, Chen CS. Development of novel adenosine monophosphate-activated protein kinase activators. Journal of Medicinal Chemistry. 53: 2552-61. PMID 20170185 DOI: 10.1021/Jm901773D  0.323
2010 Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. The Journal of Biological Chemistry. 285: 9780-91. PMID 20093366 DOI: 10.1074/Jbc.M109.065466  0.414
2009 Weng S, Wu E, Kulp SK, Wang D, Chen C, Yee LD. The antitumor effects of OSU-HDAC42, a novel histone deacetylase inhibitor, in HER-2-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14587. PMID 27963744 DOI: 10.1200/Jco.2009.27.15_Suppl.E14587  0.39
2009 Chiu HC, Kulp SK, Soni S, Wang D, Gunn JS, Schlesinger LS, Chen CS. Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrobial Agents and Chemotherapy. 53: 5236-44. PMID 19805568 DOI: 10.1128/Aac.00555-09  0.351
2009 Wang D, Chuang HC, Weng SC, Huang PH, Hsieh HY, Kulp SK, Chen CS. alpha-Tocopheryl succinate as a scaffold to develop potent inhibitors of breast cancer cell adhesion. Journal of Medicinal Chemistry. 52: 5642-8. PMID 19708661 DOI: 10.1021/Jm9002457  0.421
2009 Weng JR, Tsai CH, Omar HA, Sargeant AM, Wang D, Kulp SK, Shapiro CL, Chen CS. OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling. Carcinogenesis. 30: 1702-9. PMID 19706645 DOI: 10.1093/Carcin/Bgp202  0.392
2009 Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia (New York, N.Y.). 11: 552-63, 3 p followin. PMID 19484144 DOI: 10.1593/Neo.09204  0.447
2009 Huang PH, Wang D, Chuang HC, Wei S, Kulp SK, Chen CS. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis. 30: 1125-31. PMID 19420015 DOI: 10.1093/Carcin/Bgp112  0.484
2009 Wei S, Chuang HC, Tsai WC, Yang HC, Ho SR, Paterson AJ, Kulp SK, Chen CS. Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein. Molecular Pharmacology. 76: 47-57. PMID 19372209 DOI: 10.1124/Mol.109.055376  0.341
2009 Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, Giovannini M, Jacob A, Welling DB, Chang LS. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer (Oxford, England : 1990). 45: 1709-20. PMID 19359162 DOI: 10.1016/J.Ejca.2009.03.013  0.381
2009 Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Letters. 276: 119-24. PMID 18790559 DOI: 10.1016/J.Canlet.2008.08.008  0.447
2009 Bai L, Ma Y, Kulp SK, Wang S, Chiu C, Frissora F, Mo X, Jarjoura D, Byrd JC, Chen C, Muthusamy N. OSU-DY7, a Novel D-Tyrosinol Derivative, Mediates Cytotoxicity in Chronic Lymphocytic Leukemia and Lymphoblastic Lymphoma through p38 Mitogen-Activated Protein Kinase Pathway. Blood. 114: 3778-3778. DOI: 10.1182/Blood.V114.22.3778.3778  0.369
2008 Wei S, Yang HC, Chuang HC, Yang J, Kulp SK, Lu PJ, Lai MD, Chen CS. A novel mechanism by which thiazolidinediones facilitate the proteasomal degradation of cyclin D1 in cancer cells. The Journal of Biological Chemistry. 283: 26759-70. PMID 18650423 DOI: 10.1074/Jbc.M802160200  0.369
2008 Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. American Journal of Veterinary Research. 69: 938-45. PMID 18593248 DOI: 10.2460/Ajvr.69.7.938  0.395
2008 Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Molecular Cancer Therapeutics. 7: 800-8. PMID 18413793 DOI: 10.1158/1535-7163.MCT-07-0434  0.358
2008 Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, Kashida Y, Yamaguchi M, Chang GD, Chen CS. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Research. 68: 2820-30. PMID 18413750 DOI: 10.1158/0008-5472.Can-07-1336  0.391
2008 Yang J, Wei S, Wang DS, Wang YC, Kulp SK, Chen CS. Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents. Journal of Medicinal Chemistry. 51: 2100-7. PMID 18335975 DOI: 10.1021/Jm701212M  0.423
2008 Weng JR, Tsai CH, Kulp SK, Chen CS. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Letters. 262: 153-63. PMID 18314259 DOI: 10.1016/J.Canlet.2008.01.033  0.415
2008 Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, Muthusamy N, Byrd JC, Cheng AL, Chen CS. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Cancer Research. 68: 1204-12. PMID 18281497 DOI: 10.1158/0008-5472.Can-07-2621  0.374
2007 Alvarez FJ, Murahari S, Couto CG, Rosol TJ, Kulp SK, Chen CS, Kisseberth WC. 3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line. Veterinary and Comparative Oncology. 5: 47-58. PMID 19754801 DOI: 10.1111/J.1476-5829.2006.00117.X  0.448
2007 Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu CF, Tsai MH, Chen CS. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells. Cancer Research. 67: 7815-24. PMID 17699787 DOI: 10.1158/0008-5472.Can-07-0794  0.451
2007 Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, Kulp SK, Kirschner LS, Saji M, Chen CS, Ringel MD. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Molecular Pharmacology. 72: 1124-31. PMID 17673571 DOI: 10.1124/Mol.107.037556  0.41
2007 Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology (Baltimore, Md.). 46: 1119-30. PMID 17654699 DOI: 10.1002/Hep.21804  0.36
2007 Sargeant AM, Klein RD, Rengel RC, Clinton SK, Kulp SK, Kashida Y, Yamaguchi M, Wang X, Chen CS. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicologic Pathology. 35: 549-61. PMID 17562488 DOI: 10.1080/01926230701338966  0.409
2007 Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, Chen CS. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Research. 67: 5318-27. PMID 17545612 DOI: 10.1158/0008-5472.Can-06-3996  0.331
2006 Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5199-206. PMID 16951239 DOI: 10.1158/1078-0432.Ccr-06-0429  0.399
2006 West DA, Lucas DM, Davis ME, De Lay MD, Johnson AJ, Guster SE, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen C, Byrd JC. The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia. Blood. 108: 2807-2807. DOI: 10.1182/Blood.V108.11.2807.2807  0.402
2005 Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Research. 65: 1561-9. PMID 15735046 DOI: 10.1158/0008-5472.Can-04-1677  0.425
2005 Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, Shapiro CL, Chen CS. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Molecular Pharmacology. 67: 1342-8. PMID 15653552 DOI: 10.1124/Mol.104.007732  0.375
2004 Lin HP, Kulp SK, Tseng PH, Yang YT, Yang CC, Chen CS, Chen CS. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Molecular Cancer Therapeutics. 3: 1671-80. PMID 15634661  0.334
2004 Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Research. 64: 4309-18. PMID 15205346 DOI: 10.1158/0008-5472.Can-03-4063  0.424
2004 Jiang J, Sugimoto Y, Liu S, Chang HL, Park KY, Kulp SK, Lin YC. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Research. 24: 91-100. PMID 15015581  0.781
2004 Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Research. 64: 1444-51. PMID 14973075 DOI: 10.1158/0008-5472.Can-03-2396  0.433
2002 Liu S, Sugimoto Y, Kulp SK, Jiang J, Chang HL, Park KY, Kashida Y, Lin YC. Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. Anticancer Research. 22: 3917-23. PMID 12553013  0.76
2002 Jiang J, Ghosh PK, Kulp SK, Sugimoto Y, Liu S, Czekajewski J, Chang HL, Lin YC. Effects of gossypol on O2 consumption and CO2 production in human prostate cancer cells. Anticancer Research. 22: 1491-6. PMID 12168828  0.781
2002 Liu S, Kulp SK, Sugimoto Y, Jiang J, Chang HL, Dowd MK, Wan P, Lin YC. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Research. 22: 33-8. PMID 12017312  0.763
2002 Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Journal of the National Cancer Institute. 94: 585-91. PMID 11959891 DOI: 10.1093/Jnci/94.8.585  0.396
2002 Liu S, Kulp SK, Sugimoto Y, Jiang J, Chang HL, Lin YC. Involvement of breast epithelial-stromal interactions in the regulation of protein tyrosine phosphatase-gamma (PTPgamma) mRNA expression by estrogenically active agents. Breast Cancer Research and Treatment. 71: 21-35. PMID 11859871 DOI: 10.1023/A:1013343718942  0.775
2000 Jiang J, Kulp SK, Sugimoto Y, Liu S, Lin YC. The effects of gossypol on the invasiveness of MAT-LyLu cells and MAT-LyLu cells from the metastasized lungs of MAT-LyLu-bearing Copenhagen rats. Anticancer Research. 20: 4591-7. PMID 11205308  0.744
2000 Zheng J, Kulp SK, Zhang Y, Sugimoto Y, Dayton MA, Govindan MV, Brueggemeier RW, Lin YC. 17 beta-estradiol-regulated expression of protein tyrosine phosphatase gamma gene in cultured human normal breast and breast cancer cells. Anticancer Research. 20: 11-9. PMID 10769629  0.627
1998 Zhang Y, Kulp SK, Sugimoto Y, Brueggemeier RW, Lin YC. The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor beta1 production. International Journal of Oncology. 13: 1291-7. PMID 9824647 DOI: 10.3892/Ijo.13.6.1291  0.614
1998 Zhang Y, Kulp SK, Sugimoto Y, Farrar WB, Brueggemeier RW, Lin YC. Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells. Anticancer Research. 18: 2541-6. PMID 9703907  0.645
1998 Zhang Y, Sugimoto Y, Kulp SK, Farrar WB, Brueggemeier RW, Lin YC. Estrogen-induced keratinocyte growth factor mRNA expression in normal and cancerous human breast cells. Oncology Reports. 5: 577-83. PMID 9538155 DOI: 10.3892/Or.5.3.577  0.664
1997 Canatan H, Shidaifat F, Kulp SK, Zhang Y, Chang WY, Brueggemeir RW, Lin YC. Differential effect of keratinocyte growth factor (KGF) on aromatase activity in cultured canine prostatic epithelial cells. Endocrine Research. 23: 311-23. PMID 9430821 DOI: 10.1080/07435809709031860  0.641
1997 Shidaifat F, Canatan H, Kulp SK, Sugimoto Y, Zhang Y, Brueggemeier RW, Somers WJ, Chang WY, Wang HC, Lin YC. Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Research. 17: 1003-9. PMID 9137441  0.644
1997 Chang WY, Sugimoto Y, Shidaifat F, Kulp SK, Canatan H, Lin YC. Gossypol induces spermidine/spermine N1-acetyltransferase in canine prostate epithelial cells. Biochemical and Biophysical Research Communications. 231: 383-8. PMID 9070284 DOI: 10.1006/Bbrc.1997.6108  0.597
1996 Chang WY, Kulp SK, Sugimoto Y, Canatan H, Shidaifat F, Inpanbutr N, Lin YC. Detection of keratinocyte growth factor (KGF) messenger ribonucleic acid and immunolocalization of KGF in the canine testis. Endocrine. 5: 247-55. PMID 21153075 DOI: 10.1007/Bf02739057  0.617
1996 Shidaifat F, Canatan H, Kulp SK, Sugimoto Y, Chang WY, Zhang Y, Brueggemeier RW, Somers WJ, Lin YC. Inhibition of human prostate cancer cells growth by gossypol is associated with stimulation of transforming growth factor-beta. Cancer Letters. 107: 37-44. PMID 8913264 DOI: 10.1016/0304-3835(96)04340-6  0.684
1996 Chang WY, Shidaifat F, Chang CJ, Kulp SK, Sugimoto Y, Canatan H, Brueggemeier RW, Lin YC. Experimentally-induced prostatic hyperplasia in young beagles: a model to evaluate the chemotherapeutic effects of gossypol. Research Communications in Molecular Pathology and Pharmacology. 92: 341-60. PMID 8827831  0.557
1996 Canatan H, Chang WY, Sugimoto Y, Shidaifat F, Kulp SK, Brueggemeier RW, Lin YC. Keratinocyte growth factor (KGF/FGF-7) has a paracrine role in canine prostate: molecular cloning of mRNA encoding canine KGF. Dna and Cell Biology. 15: 247-54. PMID 8634153 DOI: 10.1089/Dna.1996.15.247  0.602
1993 Chang WY, Ohmura H, Kulp SK, Lin YC. Transforming growth factor-beta(1) regulates differentiation of porcine granulosa cells in vitro. Theriogenology. 40: 699-712. PMID 16727352 DOI: 10.1016/0093-691X(93)90206-K  0.556
1993 Kulp SK, Rikihisa Y, Lin YC, Moh PP, Li PK, Gu Y. In vitro uptake and autoradiographic localization of tritiated gossypol in Taenia taeniaeformis metacestodes. Parasitology Research. 79: 279-85. PMID 8327450 DOI: 10.1007/Bf00932182  0.499
1992 Lin YC, Hu YF, Chang CJ, Moh PP, Kulp SK. Transfer of 3H-gossypol to neonatal rats via milk of nursing dams. Life Sciences. 51: 1657-65. PMID 1435075 DOI: 10.1016/0024-3205(92)90310-L  0.474
Show low-probability matches.